CDK2 and cancer: We therefore compared the sensitivity of primary tumor cell cultures from Pax3:Foxo1a,p53 tumors with Pax3:Foxo1a,p53,Rb1 tumors for the anti-cancer agents panobinostat (LBH58; a pan-HDAC inhibitor), PD0332991 (a selective cyclin D kinase 4/6 inhibitor), SAHA (vorinostat; a HDAC inhibitor) and SNS-032 (BMS-387032; a CDK2, CDK7 and CDK9 inhibitor).